TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18623608

Group type: EXPERIMENTAL
Intervention: Estimation method based on compliance-type-specific treatment effect estimates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilevel mixture analysis using ML-EM estimation method
Number of subjects: 0
Study: 16490288

Group type: EXPERIMENTAL
Intervention: Vaccinated GPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated GPs
Number of subjects: 0
Study: 12592542

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: General Function Score
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Zung Depression Scale
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) of back pain
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes
Number of subjects: 289
Study: 10926124

Group type: EXPERIMENTAL
Intervention: audio‐CASI interview at both intake and retest
Number of subjects: 0

Group type: COMPARATOR
Intervention: face‐to‐face interview at both intake and retest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: audio‐CASI interview at intake and face‐to‐face interview at retest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: face‐to‐face interview at intake and audio‐CASI interview at retest
Number of subjects: 0
Study: 9110682

Group type: EXPERIMENTAL
Intervention: Cranberry juice cocktail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8240450

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 800 mg daily
Number of subjects: 297

Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily
Number of subjects: 297
Study: 3513767

Group type: EXPERIMENTAL
Intervention: Dazmegrel 50-200 mg p.o.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dazmegrel 100 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dazmegrel 200 mg t.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dazmegrel (all doses studied)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31882151

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (40 mg of dimethylprednisolone, injected once)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP) injection (3 separate injections, 1 week apart)
Number of subjects: 32
Study: 28939343

Group type: EXPERIMENTAL
Intervention: Nurse-led home-based exercise and cognitive behavioral therapy (E&CBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Services as usual (Control)
Number of subjects: 72
Study: 26626991

Group type: EXPERIMENTAL
Intervention: ACE910 (0.001, 0.01, 0.1, 0.3, or 1 mg/kg for Japanese; 0.1, 0.3, or 1 mg/kg for white)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ACE910
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24408120

Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate
Number of subjects: 90
Study: 21953509

Group type: EXPERIMENTAL
Intervention: 12 week community exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 19438941

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with bovine hydroxyapatite (BHA)
Number of subjects: 20
Study: 17270510

Group type: EXPERIMENTAL
Intervention: Early sensorimotor robotic training, 4 hours a week for 5 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Robotic device exposure, 30 minutes a week, twice a week (exercises with unimpaired upper limb)
Number of subjects: 35
Study: 16091494

Group type: EXPERIMENTAL
Intervention: Low-intensity training (n = 14)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (n = 12)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-intensity training (HI; n = 14)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Detraining after resistance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All treatments (including control)
Number of subjects: 50
Study: 12182293

Group type: EXPERIMENTAL
Intervention: Chin autogenous bone grafts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Iliac crest autogenous bone grafts
Number of subjects: 10
Study: 10090300

Group type: EXPERIMENTAL
Intervention: Vegetable juice consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raw or cooked vegetables consumption
Number of subjects: 0
Study: 7844684

Group type: EXPERIMENTAL
Intervention: Granisetron, 20 microgram/kg intravenously, plus up to two more doses within 24 hours if required
Number of subjects: 88

Group type: COMPARATOR
Intervention: Chlorpromazine, 0.3 to 0.5 mg/kg intravenously every 4 to 6 hours, plus dexamethasone, 2 mg/m2 intravenously every 8 hours
Number of subjects: 88
Study: 2201223

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amitriptyline plus perphenazine
Number of subjects: 38
Study: 106800

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral elementary diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients without any gastro-intestinal tract disease)
Number of subjects: 0
Study: 30946703

Group type: EXPERIMENTAL
Intervention: Metamizole and paracetamol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ibuprofen and paracetamol
Number of subjects: 200
Study: 27846055

Group type: EXPERIMENTAL
Intervention: DTaP5‐HB‐IPV‐Hib
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control (Infanrix‐hexa)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1250
Study: 25756274

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks (group 2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Open-ended ureteral catheter drainage for 48 hours (group 3)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Indwelling double J stent for 2 weeks (group 1)
Number of subjects: 99
Study: 23945445

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) treatment response
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) symptom remission
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) wellness
Number of subjects: 288
Study: 21790236

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg for 7 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 19366323

Group type: EXPERIMENTAL
Intervention: HPG containing ocular lubricant (Systane Lubricant Eye Drops; Alcon) administered four times daily (QID) for 28 days
Number of subjects: 20
Study: 17537785

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 microg/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15549468

Group type: EXPERIMENTAL
Intervention: Disposable PCA device (Coopdech Syrinjector)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electronic PCA device (IVAC PCAM PCA Syringe Pump)
Number of subjects: 40
Study: 11829199

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 14
Study: 9605675

Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bolus dose of propofol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infusion of propofol at rates of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Age, weight, height, and lean body mass as covariates
Number of subjects: 24
Study: 7531327

Group type: EXPERIMENTAL
Intervention: Maternal serum alpha‐fetoprotein (AFP) levels prior to CVS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maternal serum alpha‐fetoprotein (AFP) levels 1 week after CVS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Change in AFP levels following CVS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Change in beta hCG levels following CVS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Difference in AFP or beta hCG levels prior to and 1 week following CVS
Number of subjects: 21
Study: 3132571

Group type: EXPERIMENTAL
Intervention: Nitroglycerin depot (sustak forte)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Low-dose sustak-propranolol combinations
Number of subjects: 123
Study: 29546523

Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 44
Study: 26901221

Group type: EXPERIMENTAL
Intervention: Wheat Aleurone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wheat Bran
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study: 25697830

Group type: EXPERIMENTAL
Intervention: Isocapnic trial (end‐tidal carbon dioxide clamped at baseline levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poikilocapnic trial (end‐tidal carbon dioxide uncontrolled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both trials (hypotension with and without hypocapnia)
Number of subjects: 0
Study: 23807155

Group type: EXPERIMENTAL
Intervention: 10 mg TAF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 25 mg TAF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 40 mg TAF
Number of subjects: 38

Group type: COMPARATOR
Intervention: 300 mg TDF
Number of subjects: 38
Study: 20647087

Group type: EXPERIMENTAL
Intervention: Passive sonic irrigation system (EndoActivator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard syringe irrigation (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second session of treatment with intervisit calcium hydroxide disinfection
Number of subjects: 0
Study: 19072529

Group type: EXPERIMENTAL
Intervention: Higher internalized homonegativity (IH)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Demographic, sexual and mental health variables
Number of subjects: 675
Study: 16463838

Group type: COMPARATOR
Intervention: Cerebral electrical impedance (CEI) measured by noninvasive Brain‐Edema Monitor in healthy volunteers
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cerebral electrical impedance (CEI) in patients with ICH
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cerebral electrical impedance (CEI) in patients with arterothrombotic cerebral infarction
Number of subjects: 185
Study: 12204730

Group type: EXPERIMENTAL
Intervention: Combined drug therapy (digitalis and atenolol)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 160
Study: 10381856

Group type: EXPERIMENTAL
Intervention: Active pacing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inactive pacing
Number of subjects: 80
Study: 8921778

Group type: EXPERIMENTAL
Intervention: r-hirudin (0.1 to 0.3 mg.kg‐1.h‐1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: r-hirudin (0.05 mg.kg‐1.h‐1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: heparin (target aPTT 65 to 90 seconds or 90 to 110 seconds)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: r-hirudin (0.3 mg.kg‐1.h‐1)
Number of subjects: 163
Study: 1859005

Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (flumazenil vehicle)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 12
Study: 6345308

Group type: EXPERIMENTAL
Intervention: Galphimia glauca D4 therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 30610099

Group type: EXPERIMENTAL
Intervention: Minimal or no PAE throughout gestation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Low‐to‐moderate PAE with discontinuation early in gestation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Low‐to‐moderate PAE sustained across gestation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high PAE with reduction early in gestation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: High PAE sustained across gestation
Number of subjects: 471
Study: 30099066

Group type: EXPERIMENTAL
Intervention: 1450 ppm F (NaF) with casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1150 ppm F (SnF2) with amorphous calcium phosphate (ACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5000 ppm F (NaF) with functionalized tri-calcium phosphate (TCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5000 ppm F (NaF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1450 ppm F (MFP) with calcium sodium phosphosilicate (CSP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1450 ppm F (MFP) with CaCO3/Arg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1450 ppm F (NaF)
Number of subjects: 0
Study: 26882293

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 235

Group type: COMPARATOR
Intervention: Present‐Centered Therapy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure or Present‐Centered Therapy
Number of subjects: 235
Study: 24510401

Group type: EXPERIMENTAL
Intervention: Personalized cognitive counseling (PCC)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control (HIV testing alone)
Number of subjects: 326
Study: 22245233

Group type: EXPERIMENTAL
Intervention: Method of levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Method of limits
Number of subjects: 0
Study: 20689853

Group type: EXPERIMENTAL
Intervention: RCT abstracts
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Details of interventions
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Number of participants randomized
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Study objectives
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Trial registration details
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Method of allocation concealment
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Blinding details
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chinese vs English abstracts
Number of subjects: 332
Study: 17934053

Group type: EXPERIMENTAL
Intervention: Educational program for general practitioners based on clinical guidelines for dementia care
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Support from general practitioners to carers
Number of subjects: 25
Study: 17113890

Group type: EXPERIMENTAL
Intervention: 100 U of BTX‐A
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 150 U of BTX‐A
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 200 U of BTX‐A
Number of subjects: 75
Study: 14703416

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 50
Study: 10737133

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (nicardipine hydrochloride retard tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide)
Number of subjects: 0
Study: 9001776

Group type: EXPERIMENTAL
Intervention: Rigid lenses with low upper lid position and small palpebral aperture
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rigid lenses with high upper lid position and wide palpebral aperture
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rigid lenses interacting with the upper lid
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rigid lenses with lens center of gravity behind the corneal apex
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High riding lenses
Number of subjects: 8
Study: 1390474

Group type: EXPERIMENTAL
Intervention: Threads-up group (IUCD with threads contained in the uterine cavity)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Threads-down group (IUCD with threads passing through the cervix to the vagina)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Threads-up group
Number of subjects: 445

Group type: COMPARATOR
Intervention: Threads-down group
Number of subjects: 445
Study: 3886608

Group type: EXPERIMENTAL
Intervention: Split-Course Radiation Therapy Protocol for Carcinoma of the Base of the Tongue (RTOG #71‐02)
Number of subjects: 141
Study: 31013507

Group type: EXPERIMENTAL
Intervention: Assisted dying agreement among surrogates
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Assisted dying agreement among physicians
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Continuous deep sedation (CDS) agreement among physicians
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Continuous deep sedation (CDS) agreement among surrogates
Number of subjects: 232

Group type: COMPARATOR
Intervention: Comparison of agreement with assisted dying
Number of subjects: 232

Group type: COMPARATOR
Intervention: Comparison of agreement with CDS
Number of subjects: 232
Study: 29469593

Group type: EXPERIMENTAL
Intervention: l-carnosine (800 mg/d in two divided doses) plus methylphenidate (0.5-1.5 mg/kg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo plus methylphenidate (0.5-1.5 mg/kg/d)
Number of subjects: 56
Study: 27832693

Group type: EXPERIMENTAL
Intervention: Distance learning (DVD with a 50-minute lecture and case simulation scenario)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional learning (50-minute lecture and case simulation scenario in a workshop)
Number of subjects: 120
Study: 25301695

Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored game providing personalized feedback on drinking behavior.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (waiting list) that only fills in baseline, four and eight month follow-up measurements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored game.
Number of subjects: 0
Study: 22532165

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min) combined with cognitive training on a stop signal task (SST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive training on a stop signal task (SST) without active stimulation
Number of subjects: 22
Study: 19438956

Group type: EXPERIMENTAL
Intervention: Bioceramic molecular impregnated treatment (Ossean®)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dual acid-etched (DAE) surface
Number of subjects: 10
Study: 17996241

Group type: EXPERIMENTAL
Intervention: 1500 mg niacin for 6 weeks
Number of subjects: 20
Study: 15893402

Group type: EXPERIMENTAL
Intervention: pegylated alpha-interferon combined with lamivudine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 11883552

Group type: EXPERIMENTAL
Intervention: 250 mg B‐6
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg B‐6
Number of subjects: 12
Study: 10618689

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 114
Study: 7488415

Group type: EXPERIMENTAL
Intervention: CAV (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, cyclophosphamide 800 mg/m2 on day 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AVE (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, etoposide 60 mg/m2 i.v. on day 1 and 120 mg/m2 orally on days 2-5)
Number of subjects: 81

Group type: COMPARATOR
Intervention: CAV
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AVE
Number of subjects: 81
Study: 2009895

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.d.
Number of subjects: 163

Group type: COMPARATOR
Intervention: Nifedipine s.r. 20 mg b.d.
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 163

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 163
Study: 6616116

Group type: EXPERIMENTAL
Intervention: Pindolol (drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenic subjects
Number of subjects: 0
Study: 30406492

Group type: EXPERIMENTAL
Intervention: Spiritual intervention (six 45-minute sessions over 2 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study: 29035597

Group type: EXPERIMENTAL
Intervention: CQA coffee (300 ml/day for 2 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (300 ml/day for 2 weeks)
Number of subjects: 15
Study: 26730967

Group type: EXPERIMENTAL
Intervention: Overnight storage in water with a cleansing tablet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning and immersion in water with a cleansing tablet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Brushing and immersion in water with a cleansing tablet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Brushing and immersion in water without a cleansing tablet
Number of subjects: 13
Study: 24144876

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (ivMP)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (oMP)
Number of subjects: 49
Study: 22304681

Group type: COMPARATOR
Intervention: Transdermal testosterone patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone gel
Number of subjects: 0
Study: 19848045

Group type: EXPERIMENTAL
Intervention: Liraglutide (once-daily)
Number of subjects: 6500
Study: 17898252

Group type: EXPERIMENTAL
Intervention: Volumetric bladder ultrasonography (US)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional catheterization
Number of subjects: 93
Study: 16244196

Group type: EXPERIMENTAL
Intervention: Eccentric quadriceps training on a decline board
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concentric quadriceps training on a decline board
Number of subjects: 20